Seelos Therapeutics PE Ratio 2010-2022 | SEEL

Current and historical p/e ratio for Seelos Therapeutics (SEEL) from 2010 to 2022. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Seelos Therapeutics PE ratio as of May 27, 2022 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Seelos Therapeutics PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2022-05-27 0.62 0.00
2022-03-31 0.84 $-0.34 0.00
2021-12-31 1.63 $-0.49 0.00
2021-09-30 2.41 $-0.62 0.00
2021-06-30 2.64 $-0.60 0.00
2021-03-31 4.99 $-0.58 0.00
2020-12-31 1.58 $-0.44 0.00
2020-09-30 0.94 $-0.58 0.00
2020-06-30 1.01 $-0.62 0.00
2020-03-31 0.49 $-0.63 0.00
2019-12-31 1.34 $-4.47 0.00
2019-09-30 0.92 $-4.20 0.00
2019-06-30 2.19 $-7.67 0.00
2019-03-31 3.36 $-10.59 0.00
2018-12-31 5.76 $-10.81 0.00
2018-09-30 9.30 $-15.62 0.00
2018-06-30 11.70 $-20.72 0.00
2018-03-31 12.18 $-21.62 0.00
2017-12-31 55.20 $13.81 4.00
2017-09-30 51.30 $17.42 2.95
2017-06-30 33.90 $20.42 1.66
2017-03-31 63.30 $9.31 6.80
2016-12-31 39.00 $-48.95 0.00
2016-09-30 101.49 $-62.76 0.00
2016-06-30 119.85 $-87.09 0.00
2016-03-31 174.30 $-102.10 0.00
2015-12-31 297.00 $-114.11 0.00
2015-09-30 438.00 $-219.22 0.00
2015-06-30 513.00 $-213.21 0.00
2015-03-31 561.00 $-168.17 0.00
2014-12-31 300.00 $-156.16 0.00
2014-09-30 453.00 $-48.05 0.00
2014-06-30 675.00 $-48.05 0.00
2014-03-31 645.00 $-99.10 0.00
2013-12-31 795.00 $-159.16 0.00
2013-09-30 627.00 $-345.35 0.00
2013-06-30 705.00 $-348.35 0.00
2013-03-31 804.00 $-312.31 0.00
2012-12-31 597.00 $-285.29 0.00
2012-09-30 978.00 $-153.15 0.00
2012-06-30 1023.00 $-159.16 0.00
2012-03-31 846.00 $-276.28 0.00
2011-12-31 1548.00 $-270.27 0.00
2011-09-30 1074.00 $-426.43 0.00
2011-06-30 1437.00 $-453.45 0.00
2011-03-31 1257.00 $-477.48 0.00
2010-12-31 1041.00 $-783.60 0.00
2010-09-30 519.00 $-663.48 0.00
2010-06-30 630.00 $-648.45 0.00
2010-03-31 2070.45 $-597.35 0.00
2009-12-31 1282.50 $-192.15 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.065B $0.000B
Seelos Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focused on the development and advancement of novel therapeutics to address unmet medical needs for central nervous system disorders. The company's product pipeline consists of SLS-002, SLS-006, SLS-008, SLS-010 and SLS-012 which are in clinical stage. Seelos Therapeutics Inc., formerly known as Apricus Biosciences Inc., is based in New York, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.107B 9.86
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.761B 16.99
Biohaven Pharmaceutical Holding (BHVN) United States $10.111B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.648B 0.00
Emergent Biosolutions (EBS) United States $1.770B 7.57
Arcus Biosciences (RCUS) United States $1.376B 34.89
Myovant Sciences (MYOV) United Kingdom $1.033B 0.00
Zymeworks (ZYME) Canada $0.397B 0.00
Gelesis Holdings (GLS) United States $0.345B 0.00
Ambrx Biopharma (AMAM) United States $0.157B 0.00
Enzo Biochem (ENZ) United States $0.110B 22.60
SQZ Biotechnologies (SQZ) United States $0.100B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00